Nephroprotective activity of resveratrol in cisplatin-induced acute kidney injury
https://doi.org/10.37489/2587-7836-2026-2-73-78
EDN: TJPLHK
Abstract
Background. In Russia, more than 600,000 cases of cancer are diagnosed annually, with 18.9 % of cases diagnosed at stage IV. Chemotherapy is the primary treatment for patients with metastatic cancer. Cisplatin is a widely used chemotherapeutic agent; however, it exhibits significant nephrotoxicity, often leading to dose reduction or even complete discontinuation of treatment. Given this, preventing the development of cisplatin-induced acute kidney injury is crucial.
The aim of the study was to investigate the nephroprotective properties of resveratrol in cisplatin-induced acute kidney injury.
Materials and methods. The study was conducted at the Research Institute of Pharmacology of Living Systems, Belgorod National Research University, using 40 male Wistar laboratory rats weighing 250–300g. To simulate acute kidney injury, animals were administered cisplatin at a dose of 5 mg/kg intraperitoneally on days 1 and 8 of the experiment. For nephroprotection, resveratrol was administered orally daily at a dose of 4 mg/kg or 12 mg/kg for 2 weeks. Functional tests and laboratory studies were performed 14 days after the first cisplatin administration.
Results. The use of resveratrol in cisplatin-induced acute kidney injury was accompanied by pronounced dose-dependent nephroprotective effects, manifested by a decrease in plasma creatinine and urea levels, an increase in glomerular filtration rate, normalization of fractional sodium excretion, and an improvement in renal parenchymal microcirculation.
Conclusions. The results of the study demonstrate the potential of using resveratrol to prevent the development of cisplatin-induced acute kidney injury.
About the Authors
A. S. Netrebenko
Belgorod National Research University
Russian Federation
Russian Federation
Aleksandr S. Netrebenko – PhD, Cand. Sci. (Med.), assistant of Department of Pharmacology and Clinical Pharmacology
Belgorod
M. V. Pokrovsky
Belgorod National Research University
Russian Federation
Russian Federation
Mikhail V. Pokrovsky – PhD, Dr. Sci. (Med.), Professor, Professor of the Department of Pharmacology and Clinical Pharmacology, Head of Research Institute of Pharmacology of Living Systems
Belgorod
References
1. [Okladnikov SM, Nikitina SY. Healthcare in Russia. 2023: Stat.sb./Rosstat. Moscow, 3-46 2023. (In Russ.)].
2. Ed by AD Kaprin, et al. Moscow: MNIOI im. P.A. Gertsena — filial FGBU «NMITs radiologii» Minzdrava Rossii, 2024. (In Russ.)]. ISBN 978-5-85502-298-8.
3. [Burnasheva EV, Shatokhin YV, Snezhko IV, Matsuga AA. Kidney injury in cancer therapy. Nephrology (Saint-Petersburg). 2018;22(5):17-24 (In Russ.)]. doi: 10.24884/1561-6274-2018-22-5-17-24.
4. McSweeney KR, Gadanec LK, Qaradakhi T, et al. Mechanisms of Cisplatin-Induced Acute Kidney Injury: Pathological Mechanisms, Pharmacological Interventions, and Genetic Mitigations. Cancers (Basel). 2021 Mar 29;13(7):1572. doi: 10.3390/cancers13071572.
5. Veiga-Matos J, Remião F, Motales A. Pharmacokinetics and Toxicokinetics Roles of Membrane Transporters at Kidney Level. J Pharm Pharm Sci. 2020;23:333-356. doi: 10.18433/jpps30865.
6. Altındağ F, Ergen H. Sinapic acid alleviates cisplatin-induced acute kidney injury by mitigating oxidative stress and apoptosis. Environ Sci Pollut Res Int. 2023 Jan;30(5):12402-12411. doi: 10.1007/s11356-022-22940-x.
7. Tian B, Liu J. Resveratrol: a review of plant sources, synthesis, stability, modification and food application. J Sci Food Agric. 2020 Mar 15;100(4):1392-1404. doi: 10.1002/jsfa.10152.
8. Zhu T, Wang L, Wang LP, Wan Q. Therapeutic targets of neuroprotection and neurorestoration in ischemic stroke: Applications for natural compounds from medicinal herbs. Biomed Pharmacother. 2022 Apr;148:112719. doi: 10.1016/j.biopha.2022.112719
9. Tejada S, Capó X, Mascaró CM, et al. Hepatoprotective Effects of Resveratrol in Non-Alcoholic Fatty Live Disease. Curr Pharm Des. 2021;27(22):2558-2570. doi: 10.2174/1381612826666200417165801.
10. Hecker A, Schellnegger M, Hofmann E, et al. The impact of resveratrol on skin wound healing, scarring, and aging. Int Wound J. 2022 Jan;19(1):9-28. doi: 10.1111/iwj.13601.
11. Stupakova EG, Lazareva GA, Gureev VV, et al. L-NAME-induced Preeclampsia: correction of functional disorders of the hemostasis system with Resveratrol and Nicorandil. Research Results in Pharmacology. 2019;5(2):1-12. doi: 10.3897/rrpharmacology.5.35316.
12. Shcheblykina OV, Kostina DA, Stoyanova NG, et al. Pharmacological correction of post-contrast acute kidney injury with a functional product based on fermented grape juice. Research Results in Pharmacology. 2024;10(4):61-65. doi: 10.18413/rrpharmacology.10.546.
13. Stupakova EG, Lazareva GA, Gureev VV. Correction of morphofunctional disturbances arising when modelling Preeclampsia with resveratrol and nicorandil. Research Results: Pharmacology and Clinical Pharmacology. 2018;4(1):59-71. doi: 10.3897/rrpharmacology.4.25528.
14. Riccio BVF, Spósito L, Carvalho GC, et al . Resveratrol isoforms and conjugates: A review from biosynthesis in plants to elimination from the human body. Arch Pharm (Weinheim). 2020 Dec;353(12):e2000146. doi: 10.1002/ardp.202000146.
15. Burns J, Yokota T, Ashihara H, et al. Plant foods and herbal sources of resveratrol. J Agric Food Chem. 2002 May 22;50(11):3337-40. doi: 10.1021/jf0112973
16. Hurst WJ, Glinski JA, Miller KB, et al. Survey of the trans-resveratrol and trans-piceid content of cocoa-containing and chocolate products. J Agric Food Chem. 2008 Sep 24;56(18):8374-8. doi: 10.1021/jf801297w.
17. Baek SH, Ko JH, Lee H, et al. Resveratrol inhibits STAT3 signaling pathway through the induction of SOCS-1: Role in apoptosis induction and radiosensitization in head and neck tumor cells. Phytomedicine. 2016 May 15;23(5):566-77. doi: 10.1016/j.phymed.2016.02.011.
18. Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 1997 Jan 10;275(5297):218-20. doi: 10.1126/science.275.5297.218.
19. Harikumar KB, Kunnumakkara AB, Sethi G, et al. Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. Int J Cancer. 2010;127(2):257-268. doi:10.1002/ijc.25041. EDN: NYSWDJ
20. Do Amaral CL, Francescato HD, Coimbra TM, et al. Resveratrol attenuates cisplatin-induced nephrotoxicity in rats. Arch Toxicol. 2008 Jun;82(6):363-70. doi: 10.1007/s00204-007-0262-x.
21. Hao Q, Xiao X, Zhen J, et al. Resveratrol attenuates acute kidney injury by inhibiting death receptor mediated apoptotic pathways in a cisplatin induced rat model. Mol Med Rep. 2016 Oct;14(4):3683-9. doi: 10.3892/mmr.2016.5714.
22. Darwish MA, Abo-Youssef AM, Khalaf MM, et al. Resveratrol influences platinum pharmacokinetics: A novel mechanism in protection against cisplatin-induced nephrotoxicity. Toxicol Lett. 2018 Jun 15;290:73-82. doi: 10.1016/j.toxlet.2018.03.023.
23. Jang JY, Im E, Kim ND. Mechanism of Resveratrol-Induced Programmed Cell Death and New Drug Discovery against Cancer: A Review. Int J Mol Sci. 2022 Nov 8;23(22):13689. doi: 10.3390/ijms232213689.
24. Ren B, Kwah MX, Liu C, et AL. Resveratrol for cancer therapy: Challenges and future perspectives. Cancer Lett. 2021 Sep 1;515:63-72. doi: 10.1016/j.canlet.2021.05.001.
Review
For citations:
Netrebenko A.S., Pokrovsky M.V. Nephroprotective activity of resveratrol in cisplatin-induced acute kidney injury. Pharmacokinetics and Pharmacodynamics. 2026;(2):73-78. (In Russ.) https://doi.org/10.37489/2587-7836-2026-2-73-78. EDN: TJPLHK
Views:
52
JATS XML
Email this article 